- Christoph Zindel appointed to Managing Board of Siemens Healthineers AG
- Michael Reitermann to leave the company in amicable agreement
- Managing Board’s business responsibilities reorganized
Effective October 1, 2019, Christoph Zindel (58), head of Diagnostic Imaging of Siemens Healthineers AG since October 2018, will become a member of the Managing Board of Siemens Healthineers AG. The decision was made by the Supervisory Board of Siemens Healthineers AG at its July 25 meeting in Tarrytown, USA. At the same meeting, it was decided on the basis of an amicable agreement that Michael Reitermann (56), the member of the Managing Board who is currently responsible for the Diagnostics business segment as well as for the regional sales and service organization, will be stepping down from his post as of September 30, 2019, and leaving the company.
In connection with the changes in the Managing Board’s membership, the Board’s business responsibilities have also been reorganized. Starting October 1, 2019, Siemens Healthineers CEO Bernd Montag will be responsible for the Diagnostics business segment, the Enterprise Services and Customer Services business horizontals, and for the regions Americas (AM), Europe, Middle East and Africa (EMEA) and Asia-Pacific (AP). Managing Board member Christoph Zindel will take over the responsibility for the Imaging business segment and the Advanced Therapies business segment.
The Supervisory Board of Siemens Healthineers AG and the Supervisory Board of Siemens Healthcare GmbH have expressed their appreciation for Michael Reitermann’s many years of highly responsible work. “Michael Reitermann has demonstrated deep commitment to Siemens as a whole, and Siemens Healthineers in particular, for many years both in Germany and abroad. I want to acknowledge his achievements on behalf of the entire Supervisory Board. He has headed our Diagnostics business (DX) for many years and helped build the Siemens Healthineers Diagnostics franchise out of the three acquisitions of 2006 and 2007. He was a key contributor toward making Atellica Solution an important pillar of our strategy going forward,” said Michael Sen, Chairman of the Supervisory Boards of both Siemens Healthineers AG and Siemens Healthcare GmbH. “Successfully developing our attractive Diagnostics franchise is essential for delivering incremental growth for Siemens Healthineers – this is important for customers and investors alike. The reorganization of the Managing Board and its responsibilities provides full focus on delivering on laid out targets at the highest management level. In Christoph Zindel, with his extensive experience both in Germany and abroad, we have an outstanding manager who will lead the Imaging and Advanced Therapies businesses into a successful future, also capitalizing on the opportunities offered by Digitalization and AI,” Sen added.
Christoph Zindel has headed Diagnostic Imaging, Siemens Healthineers’ largest business area, since 2018. As a trained physician he worked for several years in surgery, he has international experience, and has held a variety of management positions during his career with the company, including in the United States.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.
Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.